Søren Bregenholt came by the BioStock Studio to discuss the main goals with this capital raise and how Alligator’s lead candidate mitazalimab has become a long-term value driver for the company.
Watch the full interview with Søren Bregenholt below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
